New study suggests CAR-T therapy monitoring time could be slashed
The study found that the risk of certain side effects peak by two weeks for lymphoma patients receiving three CAR-T therapies.
Cytiva-Cell & Gene Therapy WP 2
Spur Therapeutics to begin Phase III gene therapy trial in Gaucher disease
Advancing quality control measures vital for cell and gene therapy development
APAC leaps ahead in adoptive cell therapy space
NHS investment critical to drive cell and gene therapy research
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
Prime Medicine gets green light for trials of first-ever prime editing drug
Alzheimer’s trial doses patients with stem cell treatment directly to brain
